Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wang, Kang
DRAGON - IV, NCT04208347: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer	Active, not recruiting	2/3	580	RoW	Apatinib 250mg, Camrelizumab, S-1, Oxaliplatin, Apatinib 500mg	Ruijin Hospital	Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	12/24	08/25